

Contents lists available at ScienceDirect Technical Innovations & Patient Support in Radiation Oncology

journal homepage: www.sciencedirect.com/journal/technical-innovations-andpatient-support-in-radiation-oncology



Light flashes during proton and photon radiotherapy: A multicenter prospective observational study

Masashi Mizumoto^a, Yoshiko Oshiro^{a, b, *}, Toshio Miyamoto^c, Taisuke Sumiya^{a, b}, Motohiro Murakami^a, Keiichiro Baba^a, Shosei Shimizu^a, Takashi Iizumi^a, Haruko Numajiri^a, Kei Nakai^a, Toshiyuki Okumura^a, Kazushi Maruo^c, Takeji Sakae^a, Hideyuki Sakurai^a

^a Department of Radiation Oncology, University of Tsukuba, Tsukuba, Ibaraki, Japan

^b Department of Radiation Oncology, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan

^c Department of Biostatistics, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

ARTICLE INFO

Keywords: Radiotherapy Light flash Cherenkov Observation study Prospective

ABSTRACT

Background: Patients who receive radiation therapy sometimes complain of a light flash during irradiation. The details of the characteristics of this light have not been described. Purpose: To evaluate light flashes during photon and proton radiotherapy. Methods and Materials: A prospective observational study was performed in all adult patients (>20 years old) who received photon and proton therapy at two centers between January 2019 and August 2020, except for patients who could not communicate and those with visual abnormality. Evaluations were obtained for the presence or absence of light flashes, light darkness (7 levels), light intensity (5 levels), frequency, light movement, light flashing, and time seeing the light, using a weekly checklist. Results: A total of 650 courses were examined for 621 patients, of whom 416 received photon radiotherapy and 205 received proton beam therapy. The checklist indicated that 88 patients (16.1%) sensed light during photon or proton radiotherapy. In multivariate logistic regression analysis, the factors that were significantly associated with a light flash were a higher retina dose and younger age (p < 0.001). Light flashes were seen by only 35/524 patients (6.7%) for whom the retina was not irradiated, but by 13/33 (39.4%) and 41/64 (64.1%) with maximum isodose lines for the retina of 10-50% and 60-100%, respectively. The numbers of patients who sensed blue, purple, yellow, red, white and other colors were 52, 15, 15, 9, 16 and 8, respectively (multiple selections possible). Light movement was observed by 52 patients (59%). The location of the light was defined as near, far, and middle by 70, 13, and 5 patients, respectively. The median time the light was seen was 10 s. Conclusions: Many patients sense light flashes during radiotherapy. The retina dose and a younger age were

significantly associated with the frequency of light flashes.

Introduction

Some patients who receive radiation therapy complain that a light appears, even when they close their eyes. This phenomenon is referred to as phosphene or more recently as Cherenkov light [1–3], which is due to visible photons produced when a charged particle travels through a transparent medium at a speed greater than the speed of light in that medium [4,5]. Cherenkov light was first observed by Marie Curie in 1910 as a pale blue light from concentrated radium in a dark room [6,7]. Subsequently, Pavel Alekseyevich Cherenkov, a Russian scientist, first described blue light emission in 1934. In MV radiation therapy,

Cherenkov light is produced throughout irradiated tissue, with intensity proportional to the local absorbed dose. Several recent clinical reports indicate that patients rarely see dazzling light during radiotherapy, but light that is sensed is considered to be Cherenkov light. Tender et al. detected Cherenkov light through a patient eye during stereotactic radiotherapy [2]. However, the details of the characteristics of the light that patients see have not been described. Here, we report a multicenter prospective observational study of the perception of light flashes during photon radiotherapy and proton beam therapy.

https://doi.org/10.1016/j.tipsro.2021.11.003

Received 6 September 2021; Received in revised form 4 November 2021; Accepted 15 November 2021

2405-6324/© 2021 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy & Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

^{*} Corresponding author at: Departments of Radiation Oncology, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575 Japan. *E-mail address:* ooyoshiko@hotmail.com (Y. Oshiro).

Patients and methods

The study was performed in two centers from January 2019 to August 2020, and was approved by both institutional review boards (R01-160, Tsukuba Clinical Research & Development Organization; 2019–038, Tsukuba Medical Center Hospital). Photon radiotherapy was performed at both centers and proton beam therapy was performed at one. All adult patients (\geq 20 years old) who received photon and proton therapy in the study period were included, except for patients who could not communicate and those with visual abnormality. Visual abnormality was defined as the inability to distinguish colors on a chart with or without glasses.

Light flashes observed when the eyes were closed during irradiation were evaluated. Evaluations were made for the presence or absence of light, light darkness (7 levels), light intensity (5 levels), frequency, light movement, light flashing, and time to see the light, using a survey checklist that was completed each week. An English translation of the checklist (originally written in Japanese) is shown in Fig. 1. The light flashes were categorized as: 1 Sense of light flashes (Yes/No); 2 What color? (Purple/Blue/Yellow/Red, 1–7 darkness); 3 How strong? (1–5, 1 very weak, 3 fair, 5 very strong); 4 What kind of light (flashing, moving, feels far, feels close), 5 How long did you sense light flashes during irradiation? This checklist was generated by a team of radiation oncologists.

The dose-rate of photon therapy was 400–600 MU/min and that of proton therapy was 1300 MU/min. Proton beam irradiation was performed discontinuously. The median total dose of photon radiotherapy was 50 (8–78) Gy in 25 (1–48) fractions, and that of proton beam therapy was 63 (30–78.4) GyE in 22 (10–56) fractions.

Statistical analysis

Multivariate logistic regression, odds ratio, and linear regression models were used for binary (presence or absence of light), ordinal scale (light darkness, light intensity, frequency, light movement, and light flashing), and continuous (natural logarithm of time seeing the light) outcomes, respectively. Each model included gender, age, irradiated site (brain or head and neck, other), retina dose (maximum irradiation dose for either eye), and radiotherapy method (proton, other) as explanatory variables. Statistical significance was defined as p < 0.05.

Results

Some patients received multiple courses of radiation therapy during the study period, and thus, a total of 650 courses for 621 patients were examined. If patients received radiation therapy to multiple sites on the same day, this was counted as one course. The patient characteristics are shown in Table 1. A total of 416 patients received photon radiotherapy (3D-CRT for 297, IMRT for 119) and 205 received scattering proton beam therapy. The patients who received photon radiotherapy had a median age of 69 (28–93) years, and included 241 males and 175 females. The irradiation sites for photon radiotherapy were the brain, head and neck, chest, abdomen, pelvis and limbs in 93, 27, 147, 18, 125 and 6 cases, respectively. The patients who received proton beam therapy had a median age of 69 years (range: 20–92), and included 165 males and 40 females. The irradiation sites for proton beam therapy

Table 1
Patient characteristics.

Characteristics	Photon (N = 416)	$Proton \ (N=205)$	
Age (years)	28–93 (range)	20–92	
	69 (median)	69	
Gender			
Male	241	165	
Female	175	40	
Irradiated Site			
Brain	93	12	
Head and Neck	27	29	
Chest	147	28	
Abdomen	18	41	
Pelvis	125	94	
Limbs	6	1	
Radiotherapy Technique			
3D-CRT	297	0	
IMRT	119	0	
Proton	0	205	
Total dose and fractions			
Photon	50 (8-78) Gy in 25 (1-48) fractions		
Proton	63 (30-78.4) GyE in 22 (10-56) fractions		



5) What kind of light?

6) How long did you feel the abnormal light sensation ?

Flashing	Yes	/	No	б
Moving	Yes	/	No) About seconds
Feels far	Yes	/	No	// <u></u>
Feels close	Yes	/	No	



Technical Innovations & Patient Support in Radiation Oncology 20 (2021) 41-45

were the brain, head and neck, chest, abdomen, pelvis and limbs in 12, 29, 28, 41, 94, and 1 cases, respectively.

The survey checklist showed that 88 patients (16.1%) sensed light during photon therapy or proton beam therapy. The details of these 88 patients are shown in Table 2. Light flashes during radiotherapy were sensed by 54/97 (62%) and 34/524 (6%) of patients in whom the retina was and was not irradiated, respectively. Of the 88 patients, 73 (83%) received photon radiotherapy. The median age was 64 years, and light flashes occurred in 15/60 (25%) and 73/561 (13%) of patients aged < 50 and \geq 50 years, respectively. Light flashes were sensed by 44/105 patients (42%) with a brain tumor, 17/56 (30%) with a head and neck tumor, 18/174 (10%) with a chest tumor, and <5% with other tumors. All 27 patients who sensed a light flash during irradiation of the body trunk received photon radiotherapy.

Most of the patients observed light of a white or blue color. Red and yellow light was seen by 6 and 2 patients, respectively, and all these patients received photon radiotherapy. Of the 88 patients, 53 sensed light in every treatment, and all patients who sensed light with proton therapy had this experience during every treatment.

Factors associated with a sense of light flashes were analyzed by multivariate logistic regression analysis, and retina dose (OR = 1.031, p < 0.001) and age (OR = 0.968, p = 0.003) were identified as significant factors (Table 3). Light flashes occurred in only 35/524 patients (6.7%) in whom the retina was not irradiated, but in 13/33 (39.4%) and 41/64 (64.1%) with maximum isodose lines for the retina of 10–50% and 60–100%, respectively. For patients without retina irradiation, light flashes occurred in 4/53 (7.5%) and 30/471 (6.5%) of age \leq 50 and >50 years, respectively; whereas in patients with retina irradiation, 11/17 (64.7%) and 43/80 (53.8%) of age \leq 50 and >50 years, respectively, sensed light flashes.

The color and darkness of the light varied, but most was a blue shade color. The numbers of patients who observed blue, purple, yellow, red, white and other colors were 52, 15, 15, 9, 16, and 8, respectively, with multiple selections possible. The median darkness was 4 and females were significantly more likely to sense darker light (OR = 0.177, p < 0.001, Table 3). The median intensity was 3.0 for all patients and there was no significant factor associated with light intensity (Table 3). The irradiation method was significantly associated with a light flash (OR = 19.453, p < 0.001, Table 3). Patients who received proton therapy saw a light flash (10/16; 62.5%) more frequently than those treated with photon radiotherapy (11/72; 15.3%). Light movement was observed by 52 patients (59%). The location of the light was near, far, and middle in 70, 13, and 5 patients, respectively, and the median time the light was seen was 10 s (range: 1–180 s). No significant factor was associated with

Table 2 Rate of light flashes.

Characteristics	Light Flashes	No Light Flashes	Rate of Light Flashes (%)		
Retina					
Irradiated	54	43	62%		
Not irradiated	34	490	6%		
Age (years)					
<50	15	45	25%		
>50	73	488	13%		
Gender					
Male	50	356	12%		
Female	38	177	18%		
Irradiated Site					
Brain	44	61	42%		
Head and Neck	17	39	30%		
Chest	18	156	10%		
Abdomen	1	58	2%		
Pelvis	8	211	4%		
Limbs	0	7	0%		
Radiotherapy Technique					
3D-CRT	61	236	21%		
IMRT	12	107	10%		
Proton	15	190	7%		

Table 3

Multivariate logistic regression	analyses for a sense	of light, light	t darkness,	light
intensity, and light flashing.				

Effect	Variable	Odds ratio	95% CI	p value
Sense of	Gender (female/male)	1.150	0.648-2.043	0.633
light	Age	0.968	0.947-0.989	0.003
0	Irradiated site (brain,	1.359	0.643-2.875	0.422
	H&N/other)			
	Retina dose	1.031	1.022-1.040	< 0.001
	Radiotherapy method	0.451	0.222-0.916	0.028
	(proton/other)			
Light	Gender (female/male)	0.117	0.065-0.481	< 0.001
darkness	Age	1.024	0.986-1.064	0.218
	Irradiated site (brain,	2.809	0.879-8.975	0.081
	H&N/other)			
	Retina dose	1.002	0.990-1.015	0.726
	Radiotherapy method	0.570	0.138-2.363	0.439
	(proton/other)			
Light	Gender (female/male)	1.358	0.597-3.088	0.465
intensity	Age	1.026	0.992-1.061	0.130
	Irradiated site (brain,	0.820	0.308-2.185	0.691
	H&N/other)			
	Retina dose	1.006	0.994-1.017	0.318
	Radiotherapy method	0.855	0.257-2.846	0.798
	(proton/other)			
Light	Gender (female/male)	1.683	0.469-6.043	0.425
flashes	Age	0.979	0.933-1.027	0.380
	Irradiated site (brain,	2.370	0.529-10.622	0.260
	H&N/other)			
	Retina dose	0.996	0.980-1.013	0.680
	Radiotherapy method	19.453	3.223-117.423	0.001
	(proton/other)			

movement, location, or time.

Regarding the relationship between color and the irradiation site, patients who received radiation therapy to the brain and head and neck tended to observe blue or white light, whereas red or yellow light tended to be seen during radiotherapy to other sites. The percentages of colors for each irradiation site are shown in Fig. 2a–2d. Of the 44 patients with brain irradiation, 22 and 11 sensed blue and white light, 6 observed blue mixed color light (blue and yellow, blue and purple, etc.), and 3 saw purple light. Only one patient sensed red-yellow light. Of patients with head and neck irradiation, 11 and 1 sensed blue and white light, 4 saw blue mixed light, and one saw purple and red mixed light. In contrast, among 18 patients with chest irradiation, only 2 each saw blue and white light, and of the 9 patients with abdomen and pelvis irradiation, only one observed blue light and none saw white light.

Light was observed at a high frequency in radiotherapy to the brain or head and neck, but at a lower frequency (<50%) in radiotherapy to the body trunk (Supplemental Fig. 1). Blue or white light was observed at a high rate (>50%) during radiotherapy, whereas colors such as yellow and red were observed less frequently (Supplemental Fig. 2a-d). The RGB codes used in the checksheet are shown in Supplemental Fig. 3.

Discussion

Patients may sense light flashes during radiotherapy and this light has been suggested to be Cherenkov light. Tendler et al. visualized Cherenkov light in the eye during SRT [2]. It is generally considered that light flashes are phenomena that occur in radiotherapy to the brain or head and neck area [8–10], and in the current study, the dose to the retina was the significant factor associated with a light flash. For example, in a chordoma case treated with proton therapy at our center, the retina is covered with a full dose in the initial plan, and then the treatment field is shrunk and the retina dose is reduced to doses of 50% and 0%. Thus, we experience patients who sense a light flash with the initial plan, but the light intensity is reduced with shrinkage. This suggests that the retina and eye dose can affect light flashes.

The proton beam energy is below the Cherenkov light energy, and



Fig. 2. a) The percentages of colors received irradiation for brain. b) The percentages of colors received irradiation for head and neck (H&N). c) The percentages of colors received irradiation for abdomen and pelvis.

thus, light flashes may not be caused by Cherenkov light in proton therapy. Schardt et al. reported light flashes in cancer patients treated with heavy ions [11], with patients reporting mostly white light flashes, with 10% yellow. The ion beam energy is also below that of Cherenkov light, indicating that this light flash is also not caused by Cherenkov light. Instead, the main mechanism may be production of energy deposition by charged particles in the retina [11]. Therefore, there may be a similar mechanism of light flashes in proton therapy and ion beam therapy, but most of the color was blue to purple in proton therapy, with 19% (3/16) white. Local energy transfer differs between heavy ions and proton beams, but it is unclear if this difference gives a signal to the optic nerve.

The color of Cherenkov light is blue to purple, and in this study, blue and purple were dominant in radiotherapy to the brain or head and neck. In contrast, red and yellow light was dominant for patients with radiotherapy for the body trunk. However, the red and yellow light was observed incidentally, and no patients who received proton therapy to the trunk sensed a light flash. This may be because light sensing during radiotherapy for the trunk is due to floating secondary electrons produced in the gantry nozzle, which may directly, but incidentally, hit the retina. The energy of secondary electrons in a proton beam is lower than that in a photon beam, and therefore, no patients sensed light during proton therapy for the trunk. The difference in color may be due to the energy of the charged particle, but this is unclear.

The study found that about 50% of patients whose retina was irradiated felt light flashes during radiotherapy. This number was much higher than expected. There were no symptomatic adverse events caused by light flashes during the survey period, but some patients indicated that they felt anxious because they misunderstood the light flashes as a side effect of radiotherapy. Therefore, the results of this study are useful as a basis for an explanation to patients that seeing light flashes during radiotherapy is a common phenomenon when the retina is irradiated. This explanation is likely to reduce patient anxiety. However, the validity of the test method was not established because the checksheet was prepared only by radiation oncologists, and visual performance of the subjects was not evaluated by an ophthalmologist before the study.

In conclusion, light flashes were observed at a high rate by patients who received proton beam therapy or photon radiotherapy, and the dose to the retina was a significant factor. These flashes were also sometimes observed during radiation therapy for the body trunk.

Funding

This work was supported by the University of Tsukuba, Japan.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.tipsro.2021.11.003.

References

- Soter JA, LaRochelle EPM, Byrd BK, et al. Tracking tumor radiotherapy response in vivo with Cherenkov-excited luminescence ink imaging. Phys Med Biol 2020;65: 095004.
- [2] Tendler II, Hartford A, Jermyn M, et al. Experimentally observed cherenkov light generation in the eye during radiation therapy. Int J Radiat Oncol Biol Phys 2020; 106:422–9.
- [3] Yoon SW, Tsvankin V, Shrock Z, et al. Enhancing radiation therapy through cherenkov light-activated phototherapy. Int J Radiat Oncol Biol Phys 2018;100: 794–801.
- [4] Newman F, Asadi-Zeydabadi M, Durairaj VD, Ding M, Stuhr K, Kavanagh B. Visual sensations during megavoltage radiotherapy to the orbit attributable to Cherenkov radiation. Med Phys 2008;35:77–80.
- [5] Steidley KD, Eastman RM, Stabile RJ. Observations of visual sensations produced by Cerenkov radiation from high-energy electrons. Int J Radiat Oncol Biol Phys 1989;17:685–90.

M. Mizumoto et al.

Technical Innovations & Patient Support in Radiation Oncology 20 (2021) 41-45

- [6] Fazio GG, Jelley JV, Charman WN. Generation of Cherenkov light flashes by cosmic radiation within the eyes of the Apollo astronauts. Nature 1970;228:260–4. [7] Stevens TE, Wahlstrand JK, Kuhl J, Merlin R. Cherenkov radiation at speeds below
- the light threshold: phonon-assisted phase matching. Science 2001;291:627–30.
 [8] Blumenthal DT, Corn BW, Shtraus N. Flashes of light-radiation therapy to the brain. Radiother Oncol 2015;116:331-3.
- [9] Thariat J, Leal C, d'Ascoli A, et al. Phosphenes in patients receiving radiotherapy. Lancet Oncol 2016;17:869-71.
- [10] Mathis T, Vignot S, Leal C, et al. Mechanisms of phosphenes in irradiated patients. Oncotarget 2017;8:64579-90.
- [11] Schardt D, Kavatsyuk O, Kramer M, Durante M. Light flashes in cancer patients treated with heavy ions. Brain Stimul 2013;6:416-7.